Ипилимумаб в лечении метастатической меланомы
https://doi.org/10.21518/2079-701X-2016-10-84-92
Аннотация
Метастатическая меланома остается заболеванием, трудно поддающимся лечению. Большой прогресс в лечении пациентов с метастатической меланомой был достигнут за последние пять лет. Принципиально новым направлением в лекарственной терапии опухолей стала таргетная иммунотерапия – избирательное воздействие на сигнальные молекулы лимфоцитов. Ипилимумаб – первый препарат данного класса, который продемонстрировал клиническую эффективность у больных метастатической меланомой. В данной статье приводится обзор наиболее актуальных данных международных исследований и собственный клинический опыт применения ипилимумаба у больных метастатической меланомой.
Об авторах
И. В. САМОЙЛЕНКО
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
к.м.н.
Москва
Г. Ю. ХАРКЕВИЧ
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
к.м.н.
Москва
Л. В. ДЕМИДОВ
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
д.м.н., профессор
Москва
Список литературы
1. Coley WB. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med, 1910, 3(Surg Sect): 1-48.
2. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res, 1970, 13: 1- 27.
3. Tirelli U, Carbone A, Monfardini S, Lazzarin A, Alessi E, Pileri S. Malignant tumors in patients with human immunodeficiency virus infection: a report of 580 cases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 1989, 7(10): 1582-1583.
4. Varan A, Buyukpamukcu M, Ersoy F, Sanal O, Akyuz C, Kutluk T, Yalcin B. Malignant solid tumors associated with congenital immunodeficiency disorders. Pediatr Hematol Oncol, 2004, 21(5): 441-451.
5. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 2003, 9(12): 4296-4303.
6. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 1996, 77(7): 1303-1310.
7. Самойленко И.В., Харкевич Г.Ю., Демидов Л.В. Преодоление иммунной толерантности как способ лечения злокачественных опухолей: новые перспективы. Современная онкология, 2014, 16(1): 42-47./Samoilenko I.V., Kharkevich G.Y., Demidov L.V. Overcoming of immune tolerance as a method to treat malignant tumours: new prospects. Sovremennaya Onkologia, 2014, 16 (1): 42-47.
8. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA et al. Mutational heterogeneity in cancer and the search for new cancer- associated genes. Nature, 2013, 499(7457): 214-218.
9. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/ PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 2013, 19(19): 5300-5309.
10. van Wijk F, Nierkens S, de Jong W, Wehrens EJ, Boon L, van Kooten P, Knippels LM, Pieters R. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. J Immunol, 2007, 178(11): 6894-6900.
11. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti- CD28 monoclonal antibody TGN1412. The New England journal of medicine, 2006, 355(10): 1018-1028.
12. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 2015, 21(19): 4286-4293.
13. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 2010, 363(8): 711-723.
14. Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011, 364(26): 2517-2526.
15. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research: an official journal of the American Association for Cancer Research, 2009, 15(23): 7412-7420.
16. McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, Investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2013, 24(10): 2694-2698.
17. Maio M. Survival amalysis with 5 years of follow up in phase III study of ipilimumab and dacarbazine in metastatic melanoma: ESMO oral presentation 3704. Eur J Cancer, 2013.
18. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(17): 1889- 1894.
19. Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing pilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013, 109(1):8-13.
20. Самойленко И.В., Харкевич Г.Ю., Демидов Л.В. Применение блокатора рецепторов CTLA4 в лечении больных метастатической мела номой. РМЖ, 2015, 21(1): 4- ./Samoilenko I.V., Kharkevich G.Y., Demidov L.V. Application of CTLA4 receptor blockers in therapy of metastatic melanoma patients. RMZ, 2015, 21 (1): 4-9.
21. Gilardi L, Colandrea M, Vassallo S, Travaini LL, Paganelli G. Ipilimumab-Induced Immunomedia ted Adverse Events: Possible Pitfalls in18F-FDG PET/CT Interpretation. Clinical nuclear medicine, 2013.
22. Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer, 2015, 51(18): 2785-2791.
23. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer, 2013, 119(9): 1675-1682.
24. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine, 2015, 373(1): 23-34.
25. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine, 2015, 372(26): 2521-2532.
26. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Schadendorf D, Ferrucci PF, Smylie M et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016, 34(suppl; abstr 9505).
27. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M et al.Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatmentnaive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Journal of clinical oncology: official journal of the American Society ofClinical Oncology 2015, 33(suppl; abstr LBA1).
28. Atkins MB, Choueiri TK, Hodi FS, Thompson JA, Hwu W-J, McDermott DF, Brookes M, Tosolini A, Ebbinghaus S, Yang Z et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015, 33(suppl; abstr 3009).
29. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Jr., Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. The Lancet Oncology 2016, 17(7): 943-955.
30. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2001, 19(16): 3622-3634.
Рецензия
Для цитирования:
САМОЙЛЕНКО ИВ, ХАРКЕВИЧ ГЮ, ДЕМИДОВ ЛВ. Ипилимумаб в лечении метастатической меланомы. Медицинский Совет. 2016;(10):84-92. https://doi.org/10.21518/2079-701X-2016-10-84-92
For citation:
SAMOILENKO IV, KHARKEVICH GY, DEMIDOV LV. IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA. Meditsinskiy sovet = Medical Council. 2016;(10):84-92. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-84-92
Просмотров:
890
Послать статью по эл. почте 